The growing role of nanotechnology in combating infectious disease

Virulence

Volumn 2, Issue 5, 2011, Pages 395-401

  Blecher, Karin ^a   Nasir, Adnan ^b   Friedman, Adam ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Antibiotic; Antimicrobial; Nanotechnology; Vaccine

Indexed keywords

AMOXICILLIN; APTAMER; BACTERIAL DNA; CHITOSAN; CLINDAMYCIN; COPPER OXIDE; ERYTHROMYCIN; GENTAMICIN BONE CEMENT; GOLD NANOPARTICLE; MAGNESIUM OXIDE; NITRIC OXIDE; POLYCAPROLACTONE; POLYMER; SILVER NANOPARTICLE; TITANIUM DIOXIDE; VANCOMYCIN; ZINC OXIDE;

ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; BACILLUS MEGATERIUM; BACILLUS SUBTILIS; CANDIDA ALBICANS; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; ESCHERICHIA COLI; HUMAN; IMMUNOMODULATION; INFECTION; LISTERIA MONOCYTOGENES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NANOEMULSION; NANOTECHNOLOGY; NONHUMAN; REVIEW; SACCHAROMYCES CEREVISIAE; SALMONELLA; STAPHYLOCOCCUS AUREUS; WOUND INFECTION;

EID: 80053930419     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.2.5.17035     Document Type: Review

References (68)

1. Kim BYS, Rutka JT, Chan WC. Nanomedicine. N Eng J Med 2010; 363:2434-43.
2. Banergee M, Mallick S, Paul A, Chattopadhyay A, Ghosh S. Heightened reactive oxygen species generation in the antimicrobial activity of three component iodinated chitosan-silver nanoparticle composite. Langmuir 2010; 26:5901-8.
3. Ma Y, Zhou T, Zhao C. Preparation of chitosan-nylon-6 blended membranes containing silver ions as antibacterial materials. Carbohydr Res 2008; 343:230-7.
4. Sanpui P, Murugadoss A, Prasad PV, Ghosh SS, Chattopadhyay A. The antibacterial properties of a novel chitosan-Ag-nanoparticle composite. Int J Food Microbiol 2008; 124:142-6.
5. Qi L, Xu Z, Jiang X, Hu C, Zou X. Preparation and antibacterial activity of chitosan nanoparticles. Carbohydrate Res 2005; 339:2693-700.
6. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev 2010; 62:394-407.
7. Friedman AJ, Han G, Navati MS, Chacko M, Gunther L, Alfieri A, et al. Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide 2008; 19:12-20.
8. Potara M, Jakab E, Damert A, Popescu O, Canpean V, Astilean S. Synergistic antibacterial activity of chitosan-silver nanocomposites on Staphylococcus aureus. Nanotechnology 2011; 22:135101.
9. Mahendra R, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnology Advances 2009; 27:76-83.
10. Pal STY, Song JM. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticles? A study of the gram-negative bacterium Escherechia coli. Appl Environ Microbiol 2007; 27:1712-20.
11. Ruparelia JP, Chatterjee AK, Duttagupta SP, Mukherji S. Strain specificity in antimicrobial activity of silver and copper nanoparticles. Acta Biomater 2008; 4:707-16.
12. Martinez-Gutierrez F, Olive PL, Banuelos A, Orrantia E, Nino N, Sanchez EM, et al. Synthesis, characterization and evaluation of antimicrobial and cytotoxic effect of silver and titanium nanoparticles. Nanomedicine 2010; 6:681-8.
13. Ghosh S, Kaushik R, Nagalakshmi K, Hoti SL, Menezes GA, Harish BN, et al. Antimicrobial activity of highly stable silver nanoparticles embedded in agar-agar matrix as a thin film. Carbohydr Res 2010; 345:2220-7.
14. Shrivastava S, Bera T, Roy A, Singh G, Ramachandararao P, Dash D. Characterization of enhanced antibacterial effects of novel silver nanoparticles. Nanotechnology 2007; 18:1-9.
15. Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli. Nanomedicine 2007; 3:168-71.
16. Kim JS, Kuk E, Yu KN, Kim JH, Park SJ, Lee HJ, et al. Antimicrobial effects of silver nanoparticles. Nanomedicine 2007; 3:95-101.
17. Wu Y, Jia W, An Q, Liu Y, Chen J, Li G. Multiaction antibacterial nanofibrous membranes fabricated by electrospinning: an excellent system for antibacterial applications. Nanotechnology 2009; 20:245101.
18. Banerjee M, Mallick S, Paul A, Chattopadhyay A, Ghosh SS. Heightened reactive oxygen species generation in the antimicrobial activity of a three component iodinated chitosan-silver nanoparticle composite. Langmuir 2010; 26:5901-8.
19. Cioffi N, Torsi L, Ditaranto N, Tantillo G, Ghibelli L, Sabbatini L, et al. Copper nanoparticle/polymer composites with antifungal and bacteriostatic properties. Chem Mater 2005; 17:5255-62.
20. Ren G, Hu D, Chenge E, Vargas-Reus MA, Reip P, Allaker RP. Characterisation of copper oxide nanoparticles for antimicrobial applications. Intl J Antimicrob Agents 2009; 33:587-90.
21. Kwak SY, Kim SH, Kim SS. Hybrid organic/inorganic reverse osmosis (ro) membrane for bactericidal antifouling. (1) preparation and characterization of TiO nanoparticle self-assembled aromatic polyamide thinfilm- composite (TFC) membrane. Environ Sci Technol 2001; 35:2388-94.
22. Kim SH, Kwak S, Sohn B, Park TH. Design of TiO2 nanoparticle self-assembled aromatic polyamide thinfilm-composite (TFC) membrane as an approach to solve biofouling problem. J Memb Sci 2003; 211:157-65.
23. Lellouche J, Kahana E, Elias S, Gedanken A, Banin E. Antibiofilm activity of nanosized magnesium fluoride. Biomaterials 2009; 30:5969-78.
24. Stoimenov PK, Klinger RL, Marchin GL, Klabunde KJ. Metal oxide nanoparticles as bactericidal agents. Langmuir 2002; 18:6679-86.
25. Jin T, Sun D, Su JY, Zhang H, Sue HJ. Antimicrobial efficacy of zinc oxide quantum dots against Listeria monocytogenes, Salmonella enteritidis and Escherichia coli O157:H7. J Food Sci 2009; 74:46-52.
26. Liu Y, He L, Mustapha A, Li H, Hu ZQ, Lin M. Antibacterial activities of zinc oxide nanoparticles against Escherichia coli O157:H7. J Appl Microbiol 2009; 107:1193-201.
27. Han G, Zippin JH, Friedman A. From bench to bedside: the therapeutic potential of nitric oxide in dermatology. J Drugs Dermatol 2009; 8:586-96.
28. Englander L, Friedman A. Nitric oxide nanoparticle technology: a novel antimicrobial agent in the context of current treatment of skin and soft tissue infection. J Clin Aesthet Dermatol 2010; 3:45-50.
29. Martinez LR, Han G, Chacko M, Mihu MR, Jacobson M, Gialanella P, et al. Antimicrobial and healing efficacy of sustained release nitric oxide nanoparticles against Staphylococcus aureus skin infection. J Invest Dermatol 2009; 129:2463-9.
30. Cabrales P, Han G, Roche C, Nacharaju P, Friedman AJ, Friedman JM. Sustained release nitric oxide from long-lived circulating nanoparticles. Free Radic Biol Med 2010; 49:530-8.
31. Han G, Martinez LR, Mihu MR, Friedman AJ, Friedman JM, Nosanchuk JD. Nitric oxide releasing nanoparticles are therapeutic for Staphylococcus aureus abscesses in a murine model of infection. PLoS One 2009; 4:7804.
32. Mihu MR, Sandkovsky U, Han G, Friedman JM, Nosanchuk JD, Martinez LR. Nitrix oxide releasing nanoparticles are therapeutic for Acinetobacter baumanni wound infections. Virulence 2010; 1:62-7.
33. Pinto-Alphandary H, Andremont A, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrob Agents 2000; 13:155-68.
34. Vieira DB, Carmona-Ribeiro AM. Cationic nanoparticles for delivery of amphotericin B: preparation, characterization and activity in vitro. J Nanobiotechnology 2008; 6:6.
35. Abeylath SC, Turos E, Dickey S, Lim DV. Glyconanobiotics: Novel carbohydrated nanoparticle antibiotics for MRSA and Bacillus anthracis. Bioorg Med Chem 2008; 16:2412-8.
36. Fattal E, Rojas J, Youssef M, Couvreur P, Andremont A. Liposome-entrapped ampicillin in the treatment of experimental murine listeriosis and salmonellosis. Antimicrob Agents Chemother 1991; 35:770-2.
37. Fontana G, Pitarresi G, Tomarchio V, Carlisi B, San Biagio PL. Preparation, characterization and in vitro antimicrobial activity of ampicillin-loaded polyethylcyanoacrylate nanoparticles. Biomaterials 1998; 19:1009-17.
38. Mohammadi G, Valizadeh H, Barzegar-Jalali M, Lotfipour F, Adibkia K, Milani M, et al. Development of azithromycin-PLGA nanoparticles: physicochemical characterization and antibacterial effect against Salmonella typhi. Colloids Surf B Biointerfaces 2010; 80:34-9.
39. Dillen K, Vandervoort J, Van den Mooter G, Ludwig A. Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. Int J Pharm 2006; 314:72-82.
40. Price CI, Horton JW, Baxter CR. Liposome encapsulation: a method for enhancing the effectiveness of local antibiotics. Surgery 1994; 115:480-7.
41. Plummer EM, Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010; 3:174-96.
42. Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine 2009; 27:4388-401.
43. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009; 86:215-23.
44. Bal SM, Slutter B, van Riet E, Kruithof AC, Ding Z, Kersten GF, et al. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations. J Control Release 2010; 142:374-83.
45. Huang M. Emulsified nanoparticles containing inactivated influenza virus and cpg oligodeoxynucleotides critically influences the host immune response in mice. PLoS One 2010; 5:12270.
46. Nasir A. Nanotechnology in vaccine development: a step forward. J Invest Dermatol 2009; 129:1055-9.
47. Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med 2010; 16:224-7.
48. Combadiere B, Vogt A, Mahe B, Costagliola D, Hadam S, Bonduelle O, et al. Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial. PLoS One 2010; 5:10818.
49. Mahe B, Vogt A, Liard C, Duffy D, Abadie V, Bonduelle O, et al. Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. J Invest Dermatol 2009; 129:1156-64.
50. Semete B, Booysen LI, Kalombo L, Venter JD, Katata L, Ramalap B, et al. In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles. Toxicol Appl Pharmacol 2010; 249:158-65.
51. Csaba N, Sanchez A, Alonso MJ. PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery. J Control Release 2006; 113:164-72.
52. Rajananthanan P, Attard GS, Sheikh NA, Morrow WJ. Evaluation of novel aggregate structures as adjuvants: composition, toxicity studies and humoral responses. Vaccine 1999; 17:715-30.
53. Dykman LA, Sumaroka MV, Staroverov SA, Zaitseva IS, Bogatyrev VA. [Immunogenic properties of the colloidal gold]. Izv Akad Nauk Ser Biol 2004; 86-91.
54. Diwan M, Elamanchili P, Lane H, Gainer A, Samuel J. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J Drug Target 2003; 11:495-507.
55. Moore MD, Cookson J, Coventry VK, et al. Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics. J Biol Chem 2011; 286:2526-35.
56. Kim SK, Sims CL, Wozniak SE, Drude SH, Whitson D, Shaw RW. Antibiotic resistance in bacteria: novel metalloenzyme inhibitors. Chem Biol Drug Des 2009; 74:343-8.
57. Saccucci L, Crance JM, Colas P, Bickle M, Garin D, Iseni F. Inhibition of vaccinia virus replication by peptide aptamers. Antiviral Res 2009; 82:134-40.
58. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011; 56:95-113.
59. Makidon PE, Bielinska AU, Nigavekar SS, Janczak KW, Knowlton J, Scott AJ, et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One 2008; 3:2954.
60. Muttil P, Prego C, Garcia-Contreras L, Pulliam B, Fallon JK, Wang C, et al. Immunization of Guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route. AAPS J 2010; 12:330-7.
61. Bielinska AU, Chepurnov AA, Landers JJ, Janczak KW, Chepurnova TS, Luker GD, et al. A novel, killed-virus nasal vaccinia virus vaccine. Clin Vacc Immunol 2008; 14:348-58.
62. Helgeby A, Robson NC, Donachie AM, et al. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells. J Immunol 2006; 176:3697-706.
63. Maloy KJ, Donachie AM, Mowat AM. Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS. Eur J Immunol 1995; 25:2835-41.
64. Brunner C, Seiderer J, Schlamp A, Bidlingmaier M, Eigler A, Haimerl W, et al. Enhanced dendritic cell maturation by TNFalpha or cytidine-phosphateguanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol 2000; 165:6278-86.
65. Bacon A, Makin J, Sizer PJ, Jabbal-Gill I, Hinchcliffe M, Illum L, et al. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun 2000; 68:5764-70.
66. Florindo HF, Pandit S, Lacerda L, Goncalves LMD, Alpar HO, Almeida AJ. The enhancement of the immune response against S. equi antigens through intranasal administration of poly-3-caprolactone-based nanoparticles. Biomaterials 2009; 30:879-91.
67. Massich MD, Giljohann DA, Seferos DS, Ludlow LE, Horvath CM, Mirkin CA. Regulating immune response using polyvalent nucleic acid-gold nanoparticle conjugates. Mol Pharm 2009; 6:1934-40.
68. Bastus NG, Sanchez-Tillo E, Pujals S, Farrera C, López C, Giralt E, et al. Homogeneous conjugation of peptides onto gold nanoparticles enhances macrophage response. ACS Nano 2009; 3:1335-44.